#1 Clinical Trials Search in Europe

Dermatophagoides Pteronyssinus (503)

This article discusses clinical trials involving the use of Dermatophagoides Pteronyssinus (503), a house dust mite allergen extract, in allergy testing and treatment. These trials aim to assess the effectiveness and safety of various immunotherapy approaches for patients with allergies to common allergens like birch pollen and grass pollen. The studies focus on sublingual immunotherapy and skin prick tests to evaluate allergic responses and potential treatments.

Table of Contents

What is DERMATOPHAGOIDES PTERONYSSINUS (503)?

DERMATOPHAGOIDES PTERONYSSINUS (503) is a medical substance derived from house dust mites. Specifically, it is an extract from the species Dermatophagoides pteronyssinus, which is one of the most common house dust mites found in homes worldwide. This substance is also known by its synonym “503 House Dust Mite Dermatophagoides pteronyssinus”[1].

Medical Uses

DERMATOPHAGOIDES PTERONYSSINUS (503) is primarily used in the diagnosis and treatment of allergies related to house dust mites. It serves two main purposes:

  1. Diagnostic Tool: It is used in skin prick tests to diagnose allergies to house dust mites. These tests help doctors determine if a patient is sensitized to this specific allergen[1].
  2. Immunotherapy: While not explicitly stated in the provided clinical trial information, allergen extracts like this are often used in immunotherapy treatments to help patients build tolerance to specific allergens over time.

How is it Administered?

DERMATOPHAGOIDES PTERONYSSINUS (503) is administered as a solution for skin-prick tests. The medication is applied topically, typically in the form of drops on the skin. The maximum daily dose and total dose amount is 1 drop, and the treatment period is typically very short (around 1 time unit, likely referring to a single application)[1].

Current Clinical Trials

While the provided clinical trial information doesn’t directly focus on DERMATOPHAGOIDES PTERONYSSINUS (503), it is mentioned as part of ongoing studies related to allergies. These studies are investigating treatments for other common allergens like birch pollen and grass pollen[1][2]. This suggests that DERMATOPHAGOIDES PTERONYSSINUS (503) may be used as a comparative or control substance in these trials, or to screen participants for additional allergies.

Patient Eligibility for Clinical Trials

While the specific trials mentioned do not focus on DERMATOPHAGOIDES PTERONYSSINUS (503), they provide insight into general eligibility criteria for allergy-related studies. Typical requirements include:

  • Age between 18 and 65 years
  • Diagnosis of moderate-to-severe allergic rhinitis or rhinoconjunctivitis for at least two years
  • Positive skin prick test and specific IgE levels for the allergen being studied
  • No history of serious reactions to immunotherapy
  • No severe or uncontrolled asthma
  • No significant immune system disorders or other severe health conditions

It’s important to note that these criteria may vary for studies specifically focused on house dust mite allergies[1][2].

Safety Considerations

As with any medical treatment, there are several safety considerations to keep in mind:

  • Allergic Reactions: Even though this substance is used to diagnose allergies, it can potentially cause allergic reactions in sensitive individuals.
  • Proper Administration: The medication should only be administered by trained healthcare professionals in a controlled setting.
  • Contraindications: Patients with certain health conditions, such as severe asthma or immune disorders, may not be suitable candidates for skin prick tests or immunotherapy treatments.
  • Pregnancy and Breastfeeding: The safety of this substance during pregnancy or breastfeeding is not established in the provided information.

Always consult with a healthcare professional before undergoing any allergy tests or treatments[1].

Aspect Details
Study Type Phase II-III clinical trials
Main Focus Efficacy and safety of sublingual immunotherapy for birch and grass pollen allergies
Use of Dermatophagoides Pteronyssinus (503) Used in skin prick tests for allergy diagnosis and participant screening
Key Inclusion Criteria Adults 18-65 with moderate-to-severe allergic rhinitis/rhinoconjunctivitis, positive skin prick test, specific IgE levels ≥ 0.7 kU/L
Primary Endpoint Differences in Combined Symptom and Medication Score (CSMS) during peak pollen periods
Secondary Endpoints Quality of life changes, symptom-free days, nasal provocation test results, safety assessments
Treatment Duration Not specified in the provided information
Safety Considerations Exclusion of patients with severe asthma, immune system disorders, or previous serious reactions to immunotherapy

FAQ

  • What is Dermatophagoides Pteronyssinus (503)? Dermatophagoides Pteronyssinus (503) is a house dust mite allergen extract used in allergy testing and treatment. It is commonly used in skin prick tests to diagnose allergies to dust mites.
  • How is Dermatophagoides Pteronyssinus (503) used in these clinical trials? In these trials, Dermatophagoides Pteronyssinus (503) is used as part of a skin prick test solution to assess patients' allergic reactions. It helps determine if a patient is sensitized to dust mites as part of the inclusion criteria for the studies.
  • What are the main objectives of the clinical trials mentioned? The main objectives are to assess the efficacy and safety of sublingual immunotherapy for patients with birch pollen and grass pollen allergies. The trials aim to determine the most effective and best-tolerated doses of the treatments in terms of benefit-risk balance and symptom scores.
  • Who can participate in these clinical trials? Participants are generally adults aged 18-65 with moderate-to-severe allergic rhinitis or rhinoconjunctivitis due to specific pollens (birch or grass) for at least two years. They must meet certain criteria, including positive skin prick tests and specific IgE levels to the relevant allergens.
  • What are some of the key outcomes measured in these trials? Key outcomes include changes in combined symptom and medication scores, quality of life assessments, nasal provocation test results, and safety evaluations. The trials also measure the number of symptom-free days and the severity of allergic symptoms during peak pollen seasons.

Ongoing Clinical Trials on Dermatophagoides Pteronyssinus (503)

  • Study on the Effectiveness and Safety of Phleum Pratense Pollen Extract for Patients with Moderate-to-Severe Grass Pollen Allergy

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effectiveness and Safety of Sublingual Immunotherapy with Betula Pendula Pollen Extract for Patients with Birch Pollen Allergy

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Allergen: A substance that can cause an allergic reaction in some people, such as pollen, dust mites, or certain foods.
  • Allergic rhinitis: An allergic reaction affecting the nose, causing symptoms like sneezing, itching, and runny nose, often triggered by allergens like pollen or dust mites.
  • Dermatophagoides Pteronyssinus: A species of house dust mite that is a common cause of allergies and asthma in humans.
  • IgE (Immunoglobulin E): An antibody produced by the immune system in response to allergens, playing a key role in allergic reactions.
  • Immunotherapy: A treatment approach that aims to modify the immune system's response to allergens, potentially reducing allergic symptoms over time.
  • Nasal provocation test: A diagnostic procedure where an allergen is applied to the nasal mucosa to assess the allergic response.
  • Rhinoconjunctivitis: A condition characterized by inflammation of the nose and eyes, often caused by allergies.
  • Skin prick test: An allergy test where small amounts of potential allergens are pricked into the skin to observe any allergic reactions.
  • Sublingual immunotherapy: A form of allergy treatment where allergen extracts are placed under the tongue to help desensitize the immune system.
  • CSMS (Combined Symptom and Medication Score): A measure used in allergy studies to assess the severity of symptoms and the need for medication.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sublingual-immunotherapy-with-betula-pendula-pollen-extract-for-patients-with-birch-pollen-allergy/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-phleum-pratense-pollen-extract-for-patients-with-moderate-to-severe-grass-pollen-allergy/